NEW YORK, Nov 17 – Applied Biosystems said Friday it has obtained the exclusive license from the University of Washington to manufacture and commercialize the isotope coded affinity tagging reagents.
Applied Biosystems expects to start selling its first ICAT product in the first half of next year. Terms of the deal were not disclosed.
Ruedi Aebersold of the Institute for Systems Biology in Seattle developed the ICAT technology while he was a professor at the University of Washington. The ICAT reagents are designed to facilitate separating and tagging proteins found in tissues that researchers wish to compare.
Once the proteins are marked by the ICAT reagents they can then be analyzed by a mass spectrometer, giving researchers the opportunity to better understand how diseases behave at the molecular level.
“This technology is intended to bring added benefits in terms of identifying and quantifying important low abundance and membrane proteins,” Joseph Malandrakis, general manager of the PerSeptive Biosystems business unit of Applied Biosystems, said in a statement.
“The ICAT reagent chemistry is a platform technology that we expect to embody in a family of reagents and instrument systems over time,” he said.